Goldman says to buy Carter's ahead of margin inflection Goldman said there has been a positive inflection in live births in the U.S. for the first time since 2007 and said Carter's is the most leveraged to improving birth trends. The analyst recommends buying Carter's ahead of strong organic growth and margin improvement. Shares are Buy rated with a $102 price target.
News For CRI From The Last 14 Days
Check below for free stories on CRI the last two weeks.